Combination of eriocalyxin B and homoharringtonine exerts synergistic anti-tumor effects against t(8;21) AML

Understanding the molecular pathogenesis of acute myeloid leukemia (AML) with well-defined genomic abnormalities has facilitated the development of targeted therapeutics. Patients with t(8;21) AML frequently harbor a fusion gene RUNX1-RUNX1T1 and KIT mutations as “secondary hit”, making the disease...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Acta pharmacologica Sinica 2024-03, Vol.45 (3), p.633-645
Hauptverfasser:	Lei, Yi-chen, Chen, Xin-jie, Dai, Yu-ting, Dai, Bing, Wang, Ji-yue, Li, Miao-hui, Liu, Ping, Liu, Han, Wang, Kan-kan, Jiang, Lu, Chen, Bing
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomedical and Life Sciences Biomedicine Immunology Internal Medicine Medical Microbiology Pharmacology/Toxicology Vaccine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!